Biotech company Cencora (COR) has been making significant strides, demonstrating its robustness as a value stock for the long term. The company's earnings performance is garnering attention, with the Q2 Earnings report exceeding estimates and offering an updated FY24 Earnings Guidance. This has led the stock's price to cross above the 200-day moving average of $221.11. However, investors should note the recent disposal of a substantial number of shares by insiders. Despite a miss in Q2 2024 expectations, the biotech firm's intrinsic value is said to be 53% above its current share price, and a forthcoming US$0.51 dividend adds to investor appeal. Its changing name from AmerisourceBergen to Cencora was a strategic move that aligns with the company's global expansion. Moreover, execution of new leadership has been announced, reconfirming its financial outlook for 2024. Whilst seeing some underperformance against competitors on certain days, general view sees Cencora’s stock performing strongly overall. The company maintains its promise of economic value across all investment horizons and even has plans for a $500 million offering of senior notes.
Cencora COR News Analytics from Wed, 30 Aug 2023 07:00:00 GMT to Thu, 23 May 2024 18:38:34 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor 4
